202 related articles for article (PubMed ID: 10855639)
1. Radioiodine uptake in thyroid remnants during therapy after tracer dosimetry.
Yeung HW; Humm JL; Larson SM
J Nucl Med; 2000 Jun; 41(6):1082-5. PubMed ID: 10855639
[TBL] [Abstract][Full Text] [Related]
2. Radioiodine uptake in thyroid cancer patients after diagnostic application of low-dose 131I.
Huić D; Medvedec M; Dodig D; Popović S; Ivancević D; Pavlinovic Z; Zuvic M
Nucl Med Commun; 1996 Oct; 17(10):839-42. PubMed ID: 8951903
[TBL] [Abstract][Full Text] [Related]
3. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
[TBL] [Abstract][Full Text] [Related]
4. Radiation dose to the testes after 131I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer.
Ceccarelli C; Battisti P; Gasperi M; Fantuzzi E; Pacini F; Gualdrini G; Pierantoni MC; Luciani A; Djokich D; Pinchera A
J Nucl Med; 1999 Oct; 40(10):1716-21. PubMed ID: 10520714
[TBL] [Abstract][Full Text] [Related]
5. Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131I ablation therapy for differentiated thyroid carcinoma.
Cherk MH; Kalff V; Yap KS; Bailey M; Topliss D; Kelly MJ
Clin Endocrinol (Oxf); 2008 Dec; 69(6):957-62. PubMed ID: 18419785
[TBL] [Abstract][Full Text] [Related]
6. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation.
Jentzen W; Moldovan AS; Ruhlmann M; Görges R; Bockisch A; Rosenbaum-Krumme S
Nuklearmedizin; 2015; 54(3):137-43. PubMed ID: 25987357
[TBL] [Abstract][Full Text] [Related]
7. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
Cholewinski SP; Yoo KS; Klieger PS; O'Mara RE
J Nucl Med; 2000 Jul; 41(7):1198-202. PubMed ID: 10914909
[TBL] [Abstract][Full Text] [Related]
8. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
9. A case of stunning of lung and bone metastases of papillary thyroid cancer after a therapeutic dose (3.7 GBq) of 131I and review of the literature: implications for sequential treatments.
Leger AF; Pellan M; Dagousset F; Chevalier A; Keller I; Clerc J
Br J Radiol; 2005 May; 78(929):428-32. PubMed ID: 15845937
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.
Eschmann SM; Reischl G; Bilger K; Kupferschläger J; Thelen MH; Dohmen BM; Besenfelder H; Bares R
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):760-7. PubMed ID: 12029549
[TBL] [Abstract][Full Text] [Related]
11. Radioiodine therapy for well-differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid ablation after surgery.
Samuel AM; Rajashekharrao B
J Nucl Med; 1994 Dec; 35(12):1944-50. PubMed ID: 7989975
[TBL] [Abstract][Full Text] [Related]
12. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates.
Karam M; Gianoukakis A; Feustel PJ; Cheema A; Postal ES; Cooper JA
Nucl Med Commun; 2003 May; 24(5):489-95. PubMed ID: 12717064
[TBL] [Abstract][Full Text] [Related]
13. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma.
Muratet JP; Daver A; Minier JF; Larra F
J Nucl Med; 1998 Sep; 39(9):1546-50. PubMed ID: 9744340
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic 123I and 131I activities and radioiodine therapy. Effects on urinary iodine excretion in patients with differentiated thyroid carcinoma.
Meller B; von Hof K; Genina E; Deisting W; Meller J; Richter E; Baehre M
Nuklearmedizin; 2005; 44(6):243-8. PubMed ID: 16400384
[TBL] [Abstract][Full Text] [Related]
15. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
[TBL] [Abstract][Full Text] [Related]
16. Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome.
Logue JP; Tsang RW; Brierley JD; Simpson WJ
Br J Radiol; 1994 Nov; 67(803):1127-31. PubMed ID: 7820407
[TBL] [Abstract][Full Text] [Related]
17. Impact of 131I diagnostic activities on the biokinetics of thyroid remnants.
Lassmann M; Luster M; Hänscheid H; Reiners C
J Nucl Med; 2004 Apr; 45(4):619-25. PubMed ID: 15073258
[TBL] [Abstract][Full Text] [Related]
18. Short-term effectiveness of low-dose radioiodune ablative treatment of thyroid remnants after thyroidectomy for differentiated thyroid cancer.
Vermiglio F; Violi MA; Finocchiaro MD; Baldari S; Castagna MG; Moleti M; Mattina F; Pio Lo Presti V; Bonanno N; Trimarchi F
Thyroid; 1999 Apr; 9(4):387-91. PubMed ID: 10319946
[TBL] [Abstract][Full Text] [Related]
19. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer.
Liu B; Huang R; Kuang A; Zhao Z; Zeng Y; Wang J; Tian R
Med Phys; 2011 Oct; 38(10):5412-9. PubMed ID: 21992360
[TBL] [Abstract][Full Text] [Related]
20. Dosimetry in differentiated thyroid carcinoma (12-1402R).
Minguez P; Genolla J; Celeiro JJ; Fombellida JC
Med Phys; 2013 Jan; 40(1):012502. PubMed ID: 23298113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]